IGM Biosciences
IGMS
IGMS was delisted on the 13th of August, 2025.
81 hedge funds and large institutions have $305M invested in IGM Biosciences in 2022 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 35 increasing their positions, 23 reducing their positions, and 15 closing their positions.
547% more call options, than puts
Call options by funds: $1.07M | Put options by funds: $165K
52% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 23
0.48% more ownership
Funds ownership: 61.06% → 61.53% (+0.48%)
12% less funds holding
Funds holding: 92 → 81 (-11)
24% less capital invested
Capital invested by funds: $402M → $305M (-$97M)
60% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 15
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$13.8M |
| 2 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$2.2M |
| 3 |
Renaissance Technologies
New York
|
+$1.6M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.14M |
| 5 |
D.E. Shaw & Co
New York
|
+$1.05M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$13.3M |
| 2 |
Alkeon Capital Management
New York
|
-$2.57M |
| 3 |
Goldman Sachs
New York
|
-$1.01M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
-$1M |
| 5 |
Voloridge Investment Management
Jupiter,
Florida
|
-$885K |
IGMS Hedge Fund Activity: Q4 2022 in Review
81 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in IGM Biosciences (IGMS) for Q4 2022, worth a combined $305M — down 24% from $402M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of IGMS and 6 opened new positions — a net loss of 9 holders — while 23 trimmed existing stakes and 35 added.
The largest buyer was Fidelity Investments, adding an estimated $13.8M. The largest seller was T. Rowe Price Investment Management, exiting entirely with an estimated $13.3M sold.
- 81 institutional investors held IGM Biosciences (IGMS) as of Q4 2022, down from 92 in Q3 2022.
- Funds reported $305M of IGM Biosciences stock for Q4 2022, down 24% quarter-over-quarter.
- 6 funds opened new IGM Biosciences positions in Q4 2022 and 15 closed out, a net change of -9 holders.
- The largest IGM Biosciences buyer in Q4 2022 was Fidelity Investments, an estimated $13.8M added.
- The largest IGM Biosciences seller in Q4 2022 was T. Rowe Price Investment Management, an estimated $13.3M sold.
Based on aggregated 13F filings for Q4 2022.